FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916812372> ?p ?o ?g. }

• W2916812372 abstract "Background: In locally advanced breast cancer, neoadjuvant chemotherapy may reduce tumor dimension and allow breast-conserving surgeries. However, it is not yet possible to predict which patients will benefit from neoadjuvant chemotherapy, as some patients may not experience tumor reduction, especially in luminal tumor samples. Tumor behavior reflects an intense crosstalk between malignant and stromal cells; however, little importance has been placed on the influence of the stromal cell in tumor response to chemotherapy. Objective: Our aim was to evaluate whether a stromal cell transcriptional signature might be associated with response to neoadjuvant anthracycline and taxane, in locally advanced luminal breast cancer, using a direct approach of stromal cell selection. Methodology: Twenty-nine patients diagnosed with locally advanced luminal breast cancer received neoadjuvant chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel). Breast cancer slices were submitted to laser-capture microdissection (LCM) to select stromal cells. Total RNA from stromal enriched cells were isolated using Arcturus PicoPure RNA isolation (Life technologies) according to the manufacturer9s protocol. Linearly amplified two-round RiboAmp HSPlus2-round and Low Input Quick Amp (Agilent Technologies) protocols were adapted to optimize the amplification for the small numbers of cells produced by LCM. The labelled cRNAs were hybridized onto the Sure Print G3 (8×60K, Agilent Technologies). After having washed the slides, the arrays were scanned with the Agilent Bundle Model B Microarray Scanner System (Agilent Technologies). Scanned image files were visually inspected for artifacts, and the fluorescence intensities were extracted and preprocessed with Agilent Feature Extraction software (v10.7.1) and to normalize the results geneSpring GX12.1 software (Agilent Technologies) was used. Expression levels were compared using MultiExperiment Viewer (MeV) software, applying significance analysis of microarrays (SAM). Gene set enrichment analysis (GSEA) was used to identify whether predefined gene sets might associate with gene expression differences between phenotypes (http://software.broadinstitute.org/gsea/index.jsp). This methodology makes it possible to detect situations where all genes, in a predefined set, change in a small but coordinated way. Results: In estrogen receptor (ER) positive tumors, GSEA (FDR Gene sets associated with tumor non-down-staging (GSEA FDR Conclusion: A stromal signature associated with immune response in locally advanced luminal breast cancer may be associated with tumor down-staging following neoadjuvant chemotherapy. Financial Support: FAPESP 09/100088-7. Citation Format: Maria Lucia H. Katayama, Rene A da Costa Vieira, Rosimeire A. Roela, Victor P. Andrade, Luiz Guilherme C. A. de Lima, Giselly Encinas, Ligia M. Kerr, Simone Maistro, M. Mitzi Brentani, Maria A. A. Koike Folgueira. Stromal cell signature in luminal breast cancer associated with response to neoadjuvant chemotherapy [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; Sao Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr A22." @default.
• W2916812372 created "2019-03-02" @default.
• W2916812372 creator A5012552798 @default.
• W2916812372 creator A5016720580 @default.
• W2916812372 creator A5026107119 @default.
• W2916812372 creator A5038084423 @default.
• W2916812372 creator A5038478455 @default.
• W2916812372 creator A5056346234 @default.
• W2916812372 creator A5060616667 @default.
• W2916812372 creator A5074769527 @default.
• W2916812372 creator A5076785471 @default.
• W2916812372 creator A5079667513 @default.
• W2916812372 date "2018-01-01" @default.
• W2916812372 modified "2023-09-25" @default.
• W2916812372 title "Abstract A22: Stromal cell signature in luminal breast cancer associated with response to neoadjuvant chemotherapy" @default.
• W2916812372 doi "https://doi.org/10.1158/1557-3265.tcm17-a22" @default.
• W2916812372 hasPublicationYear "2018" @default.
• W2916812372 type Work @default.
• W2916812372 sameAs 2916812372 @default.
• W2916812372 citedByCount "0" @default.
• W2916812372 crossrefType "proceedings-article" @default.
• W2916812372 hasAuthorship W2916812372A5012552798 @default.
• W2916812372 hasAuthorship W2916812372A5016720580 @default.
• W2916812372 hasAuthorship W2916812372A5026107119 @default.
• W2916812372 hasAuthorship W2916812372A5038084423 @default.
• W2916812372 hasAuthorship W2916812372A5038478455 @default.
• W2916812372 hasAuthorship W2916812372A5056346234 @default.
• W2916812372 hasAuthorship W2916812372A5060616667 @default.
• W2916812372 hasAuthorship W2916812372A5074769527 @default.
• W2916812372 hasAuthorship W2916812372A5076785471 @default.
• W2916812372 hasAuthorship W2916812372A5079667513 @default.
• W2916812372 hasConcept C121608353 @default.
• W2916812372 hasConcept C126322002 @default.
• W2916812372 hasConcept C142724271 @default.
• W2916812372 hasConcept C143998085 @default.
• W2916812372 hasConcept C16930146 @default.
• W2916812372 hasConcept C2776694085 @default.
• W2916812372 hasConcept C2776802502 @default.
• W2916812372 hasConcept C2777292972 @default.
• W2916812372 hasConcept C2778292576 @default.
• W2916812372 hasConcept C2781303535 @default.
• W2916812372 hasConcept C502942594 @default.
• W2916812372 hasConcept C530470458 @default.
• W2916812372 hasConcept C71924100 @default.
• W2916812372 hasConceptScore W2916812372C121608353 @default.
• W2916812372 hasConceptScore W2916812372C126322002 @default.
• W2916812372 hasConceptScore W2916812372C142724271 @default.
• W2916812372 hasConceptScore W2916812372C143998085 @default.
• W2916812372 hasConceptScore W2916812372C16930146 @default.
• W2916812372 hasConceptScore W2916812372C2776694085 @default.
• W2916812372 hasConceptScore W2916812372C2776802502 @default.
• W2916812372 hasConceptScore W2916812372C2777292972 @default.
• W2916812372 hasConceptScore W2916812372C2778292576 @default.
• W2916812372 hasConceptScore W2916812372C2781303535 @default.
• W2916812372 hasConceptScore W2916812372C502942594 @default.
• W2916812372 hasConceptScore W2916812372C530470458 @default.
• W2916812372 hasConceptScore W2916812372C71924100 @default.
• W2916812372 hasLocation W29168123721 @default.
• W2916812372 hasOpenAccess W2916812372 @default.
• W2916812372 hasPrimaryLocation W29168123721 @default.
• W2916812372 hasRelatedWork W1978297697 @default.
• W2916812372 hasRelatedWork W2016162191 @default.
• W2916812372 hasRelatedWork W2035944700 @default.
• W2916812372 hasRelatedWork W2040855822 @default.
• W2916812372 hasRelatedWork W2051862972 @default.
• W2916812372 hasRelatedWork W2136101641 @default.
• W2916812372 hasRelatedWork W2151896635 @default.
• W2916812372 hasRelatedWork W2171304384 @default.
• W2916812372 hasRelatedWork W2315120232 @default.
• W2916812372 hasRelatedWork W2406732508 @default.
• W2916812372 hasRelatedWork W2592558231 @default.
• W2916812372 hasRelatedWork W2605342865 @default.
• W2916812372 hasRelatedWork W2793867126 @default.
• W2916812372 hasRelatedWork W2920046699 @default.
• W2916812372 hasRelatedWork W2936448501 @default.
• W2916812372 hasRelatedWork W2944129595 @default.
• W2916812372 hasRelatedWork W2954375134 @default.
• W2916812372 hasRelatedWork W2998957960 @default.
• W2916812372 hasRelatedWork W3013503962 @default.
• W2916812372 hasRelatedWork W3182479079 @default.
• W2916812372 isParatext "false" @default.
• W2916812372 isRetracted "false" @default.
• W2916812372 magId "2916812372" @default.
• W2916812372 workType "article" @default.